Tim Mayleben, Esperion CEO
Esperion's struggling-to-market, would-be blockbuster finds fresh infusion of cash
A year after winning approval for their heart disease pill, Esperion is still struggling to sell it.
Burned by a mid-pandemic launch, the Ann Arbor …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
